Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation : I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021
IntroductionTwo large multicentre European hospital networks have estimated vaccine effectiveness (VE) against COVID-19 since 2021.AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in hospitalised severe acute respiratory illness (SARI) patients ≥ 20 years, combining data from these networks during Alpha (March-June)- and Delta (June-December)-dominant periods, 2021.MethodsForty-six participating hospitals across 14 countries follow a similar generic protocol using the test-negative case-control design. We defined complete primary series vaccination (PSV) as two doses of a two-dose or one of a single-dose vaccine ≥ 14 days before onset.ResultsWe included 1,087 cases (538 controls) and 1,669 cases (1,442 controls) in the Alpha- and Delta-dominant periods, respectively. During the Alpha period, VE against hospitalisation with SARS-CoV2 for complete Comirnaty PSV was 85% (95% CI: 69-92) overall and 75% (95% CI: 42-90) in those aged ≥ 80 years. During the Delta period, among SARI patients ≥ 20 years with symptom onset ≥ 150 days from last PSV dose, VE for complete Comirnaty PSV was 54% (95% CI: 18-74). Among those receiving Comirnaty PSV and mRNA booster (any product) ≥ 150 days after last PSV dose, VE was 91% (95% CI: 57-98). In time-since-vaccination analysis, complete all-product PSV VE was > 90% in those with their last dose < 90 days before onset; ≥ 70% in those 90-179 days before onset.ConclusionsOur results from this EU multi-country hospital setting showed that VE for complete PSV alone was higher in the Alpha- than the Delta-dominant period, and addition of a first booster dose during the latter period increased VE to over 90%.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
---|---|
Enthalten in: |
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin - 28(2023), 47 vom: 23. Nov. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Rose, Angela Mc [VerfasserIn] |
---|
Links: |
---|
Themen: |
Alpha |
---|
Anmerkungen: |
Date Completed 27.11.2023 Date Revised 12.01.2024 published: Print Citation Status MEDLINE |
---|
doi: |
10.2807/1560-7917.ES.2023.28.47.2300186 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM364889217 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM364889217 | ||
003 | DE-627 | ||
005 | 20240114234305.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.2807/1560-7917.ES.2023.28.47.2300186 |2 doi | |
028 | 5 | 2 | |a pubmed24n1257.xml |
035 | |a (DE-627)NLM364889217 | ||
035 | |a (NLM)37997666 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Rose, Angela Mc |e verfasserin |4 aut | |
245 | 1 | 0 | |a Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation |b I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 27.11.2023 | ||
500 | |a Date Revised 12.01.2024 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a IntroductionTwo large multicentre European hospital networks have estimated vaccine effectiveness (VE) against COVID-19 since 2021.AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in hospitalised severe acute respiratory illness (SARI) patients ≥ 20 years, combining data from these networks during Alpha (March-June)- and Delta (June-December)-dominant periods, 2021.MethodsForty-six participating hospitals across 14 countries follow a similar generic protocol using the test-negative case-control design. We defined complete primary series vaccination (PSV) as two doses of a two-dose or one of a single-dose vaccine ≥ 14 days before onset.ResultsWe included 1,087 cases (538 controls) and 1,669 cases (1,442 controls) in the Alpha- and Delta-dominant periods, respectively. During the Alpha period, VE against hospitalisation with SARS-CoV2 for complete Comirnaty PSV was 85% (95% CI: 69-92) overall and 75% (95% CI: 42-90) in those aged ≥ 80 years. During the Delta period, among SARI patients ≥ 20 years with symptom onset ≥ 150 days from last PSV dose, VE for complete Comirnaty PSV was 54% (95% CI: 18-74). Among those receiving Comirnaty PSV and mRNA booster (any product) ≥ 150 days after last PSV dose, VE was 91% (95% CI: 57-98). In time-since-vaccination analysis, complete all-product PSV VE was > 90% in those with their last dose < 90 days before onset; ≥ 70% in those 90-179 days before onset.ConclusionsOur results from this EU multi-country hospital setting showed that VE for complete PSV alone was higher in the Alpha- than the Delta-dominant period, and addition of a first booster dose during the latter period increased VE to over 90% | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Alpha | |
650 | 4 | |a Delta | |
650 | 4 | |a Europe | |
650 | 4 | |a SARS-CoV-2 | |
650 | 4 | |a hospital | |
650 | 4 | |a vaccine effectiveness | |
650 | 7 | |a BNT162 Vaccine |2 NLM | |
650 | 7 | |a RNA, Viral |2 NLM | |
700 | 1 | |a Nicolay, Nathalie |e verfasserin |4 aut | |
700 | 1 | |a Sandonis Martín, Virginia |e verfasserin |4 aut | |
700 | 1 | |a Mazagatos, Clara |e verfasserin |4 aut | |
700 | 1 | |a Petrović, Goranka |e verfasserin |4 aut | |
700 | 1 | |a Niessen, F Annabel |e verfasserin |4 aut | |
700 | 1 | |a Machado, Ausenda |e verfasserin |4 aut | |
700 | 1 | |a Launay, Odile |e verfasserin |4 aut | |
700 | 1 | |a Denayer, Sarah |e verfasserin |4 aut | |
700 | 1 | |a Seyler, Lucie |e verfasserin |4 aut | |
700 | 1 | |a Baruch, Joaquin |e verfasserin |4 aut | |
700 | 1 | |a Burgui, Cristina |e verfasserin |4 aut | |
700 | 1 | |a Loghin, Isabela I |e verfasserin |4 aut | |
700 | 1 | |a Domegan, Lisa |e verfasserin |4 aut | |
700 | 1 | |a Vaikutytė, Roberta |e verfasserin |4 aut | |
700 | 1 | |a Husa, Petr |e verfasserin |4 aut | |
700 | 1 | |a Panagiotakopoulos, George |e verfasserin |4 aut | |
700 | 1 | |a Aouali, Nassera |e verfasserin |4 aut | |
700 | 1 | |a Dürrwald, Ralf |e verfasserin |4 aut | |
700 | 1 | |a Howard, Jennifer |e verfasserin |4 aut | |
700 | 1 | |a Pozo, Francisco |e verfasserin |4 aut | |
700 | 1 | |a Sastre-Palou, Bartolomé |e verfasserin |4 aut | |
700 | 1 | |a Nonković, Diana |e verfasserin |4 aut | |
700 | 1 | |a Knol, Mirjam J |e verfasserin |4 aut | |
700 | 1 | |a Kislaya, Irina |e verfasserin |4 aut | |
700 | 1 | |a Luong Nguyen, Liem Binh |e verfasserin |4 aut | |
700 | 1 | |a Bossuyt, Nathalie |e verfasserin |4 aut | |
700 | 1 | |a Demuyser, Thomas |e verfasserin |4 aut | |
700 | 1 | |a Džiugytė, Aušra |e verfasserin |4 aut | |
700 | 1 | |a Martínez-Baz, Iván |e verfasserin |4 aut | |
700 | 1 | |a Popescu, Corneliu |e verfasserin |4 aut | |
700 | 1 | |a Duffy, Róisín |e verfasserin |4 aut | |
700 | 1 | |a Kuliešė, Monika |e verfasserin |4 aut | |
700 | 1 | |a Součková, Lenka |e verfasserin |4 aut | |
700 | 1 | |a Michelaki, Stella |e verfasserin |4 aut | |
700 | 1 | |a Simon, Marc |e verfasserin |4 aut | |
700 | 1 | |a Reiche, Janine |e verfasserin |4 aut | |
700 | 1 | |a Otero-Barrós, María Teresa |e verfasserin |4 aut | |
700 | 1 | |a Lovrić Makarić, Zvjezdana |e verfasserin |4 aut | |
700 | 1 | |a Bruijning-Verhagen, Patricia Cjl |e verfasserin |4 aut | |
700 | 1 | |a Gomez, Verónica |e verfasserin |4 aut | |
700 | 1 | |a Lesieur, Zineb |e verfasserin |4 aut | |
700 | 1 | |a Barbezange, Cyril |e verfasserin |4 aut | |
700 | 1 | |a Van Nedervelde, Els |e verfasserin |4 aut | |
700 | 1 | |a Borg, Maria-Louise |e verfasserin |4 aut | |
700 | 1 | |a Castilla, Jesús |e verfasserin |4 aut | |
700 | 1 | |a Lazar, Mihaela |e verfasserin |4 aut | |
700 | 1 | |a O'Donnell, Joan |e verfasserin |4 aut | |
700 | 1 | |a Jonikaitė, Indrė |e verfasserin |4 aut | |
700 | 1 | |a Demlová, Regina |e verfasserin |4 aut | |
700 | 1 | |a Amerali, Marina |e verfasserin |4 aut | |
700 | 1 | |a Wirtz, Gil |e verfasserin |4 aut | |
700 | 1 | |a Tolksdorf, Kristin |e verfasserin |4 aut | |
700 | 1 | |a Valenciano, Marta |e verfasserin |4 aut | |
700 | 1 | |a Bacci, Sabrina |e verfasserin |4 aut | |
700 | 1 | |a Kissling, Esther |e verfasserin |4 aut | |
700 | 0 | |a I-MOVE-COVID-19 hospital study team |e verfasserin |4 aut | |
700 | 0 | |a VEBIS hospital study team |e verfasserin |4 aut | |
700 | 0 | |a Members of the I-MOVE-COVID-19 and VEBIS hospital study teams (in addition to the named authors) |e verfasserin |4 aut | |
700 | 1 | |a Karabuva, Svjetlana |e investigator |4 oth | |
700 | 1 | |a Petrić, Petra Tomaš |e investigator |4 oth | |
700 | 1 | |a Marković, Marija |e investigator |4 oth | |
700 | 1 | |a Ljubičić, Sandra |e investigator |4 oth | |
700 | 1 | |a Mahmutović, Bojana |e investigator |4 oth | |
700 | 1 | |a Tabain, Irena |e investigator |4 oth | |
700 | 1 | |a Smoljo, Petra |e investigator |4 oth | |
700 | 1 | |a Novosel, Iva Pem |e investigator |4 oth | |
700 | 1 | |a Melillo, Tanya |e investigator |4 oth | |
700 | 1 | |a Cauchi, John Paul |e investigator |4 oth | |
700 | 1 | |a Lissoir, Benédicte |e investigator |4 oth | |
700 | 1 | |a Holemans, Xavier |e investigator |4 oth | |
700 | 1 | |a Hainaut, Marc |e investigator |4 oth | |
700 | 1 | |a Dauby, Nicolas |e investigator |4 oth | |
700 | 1 | |a Delaere, Benedicte |e investigator |4 oth | |
700 | 1 | |a Bourgeois, Marc |e investigator |4 oth | |
700 | 1 | |a Petit, Evelyn |e investigator |4 oth | |
700 | 1 | |a Reynders, Marijke |e investigator |4 oth | |
700 | 1 | |a Jouck, Door |e investigator |4 oth | |
700 | 1 | |a Magerman, Koen |e investigator |4 oth | |
700 | 1 | |a Bleyen, Marieke |e investigator |4 oth | |
700 | 1 | |a Vermeulen, Melissa |e investigator |4 oth | |
700 | 1 | |a Fierens, Sébastien |e investigator |4 oth | |
700 | 1 | |a Dufrasne, François |e investigator |4 oth | |
700 | 1 | |a Daelemans, Siel |e investigator |4 oth | |
700 | 1 | |a Al Kerwi, Ala'a |e investigator |4 oth | |
700 | 1 | |a Berthet, Francoise |e investigator |4 oth | |
700 | 1 | |a Fagherazzi, Guy |e investigator |4 oth | |
700 | 1 | |a Alexandre, Myriam |e investigator |4 oth | |
700 | 1 | |a Bennett, Charlene |e investigator |4 oth | |
700 | 1 | |a Christle, Jim |e investigator |4 oth | |
700 | 1 | |a Connell, Jeff |e investigator |4 oth | |
700 | 1 | |a Doran, Peter |e investigator |4 oth | |
700 | 1 | |a Feeney, Laura |e investigator |4 oth | |
700 | 1 | |a Maharjan, Binita |e investigator |4 oth | |
700 | 1 | |a McDermott, Sinead |e investigator |4 oth | |
700 | 1 | |a McNamara, Rosa |e investigator |4 oth | |
700 | 1 | |a Nurdin, Nadra |e investigator |4 oth | |
700 | 1 | |a Cissé, Salif Mamadou |e investigator |4 oth | |
700 | 1 | |a L'Honneur, Anne-Sophie |e investigator |4 oth | |
700 | 1 | |a Duval, Xavier |e investigator |4 oth | |
700 | 1 | |a Costa, Yolande |e investigator |4 oth | |
700 | 1 | |a Nadhira, Fidouh |e investigator |4 oth | |
700 | 1 | |a Galtier, Florence |e investigator |4 oth | |
700 | 1 | |a Crantelle, Laura |e investigator |4 oth | |
700 | 1 | |a Foulongne, Vincent |e investigator |4 oth | |
700 | 1 | |a Vanhems, Phillipe |e investigator |4 oth | |
700 | 1 | |a Amour, Sélilah |e investigator |4 oth | |
700 | 1 | |a Lina, Bruno |e investigator |4 oth | |
700 | 1 | |a Lainé, Fabrice |e investigator |4 oth | |
700 | 1 | |a Gallais, Laetitia |e investigator |4 oth | |
700 | 1 | |a Lagathu, Gisèle |e investigator |4 oth | |
700 | 1 | |a Maisa, Anna |e investigator |4 oth | |
700 | 1 | |a Saidi, Yacine |e investigator |4 oth | |
700 | 1 | |a Durier, Christine |e investigator |4 oth | |
700 | 1 | |a Bauer, Rebecca |e investigator |4 oth | |
700 | 1 | |a Rodrigues, Ana Paula |e investigator |4 oth | |
700 | 1 | |a Silva, Adriana |e investigator |4 oth | |
700 | 1 | |a Guiomar, Raquel |e investigator |4 oth | |
700 | 1 | |a Tavares, Margarida |e investigator |4 oth | |
700 | 1 | |a Pereira, Débora |e investigator |4 oth | |
700 | 1 | |a Manata, Maria José |e investigator |4 oth | |
700 | 1 | |a Gruner, Heidi |e investigator |4 oth | |
700 | 1 | |a Almeida, André |e investigator |4 oth | |
700 | 1 | |a Pinto, Paula |e investigator |4 oth | |
700 | 1 | |a Bárbara, Cristina |e investigator |4 oth | |
700 | 1 | |a Casado, Itziar |e investigator |4 oth | |
700 | 1 | |a Miqueleiz, Ana |e investigator |4 oth | |
700 | 1 | |a Navascués, Ana |e investigator |4 oth | |
700 | 1 | |a Trobajo-Sanmartín, Camino |e investigator |4 oth | |
700 | 1 | |a Fernández-Huerta, Miguel |e investigator |4 oth | |
700 | 1 | |a Portillo, María Eugenia |e investigator |4 oth | |
700 | 1 | |a Ezpeleta, Carmen |e investigator |4 oth | |
700 | 1 | |a Egüés, Nerea |e investigator |4 oth | |
700 | 1 | |a Cenoz, Manuel García |e investigator |4 oth | |
700 | 1 | |a Ardanaz, Eva |e investigator |4 oth | |
700 | 1 | |a Guevara, Marcela |e investigator |4 oth | |
700 | 1 | |a Moreno-Iribas, Conchi |e investigator |4 oth | |
700 | 1 | |a Orlíková, Hana |e investigator |4 oth | |
700 | 1 | |a Dorobat, Carmen Mihaela |e investigator |4 oth | |
700 | 1 | |a Manciuc, Carmen |e investigator |4 oth | |
700 | 1 | |a Florescu, Simin Aysel |e investigator |4 oth | |
700 | 1 | |a Marin, Alexandru |e investigator |4 oth | |
700 | 1 | |a Dinu, Sorin |e investigator |4 oth | |
700 | 1 | |a Pascu, Catalina |e investigator |4 oth | |
700 | 1 | |a Ivanciuc, Alina |e investigator |4 oth | |
700 | 1 | |a Bistriceanu, Iulia |e investigator |4 oth | |
700 | 1 | |a Oprea, Mihaela |e investigator |4 oth | |
700 | 1 | |a Mihai, Maria Elena |e investigator |4 oth | |
700 | 1 | |a Buda, Silke |e investigator |4 oth | |
700 | 1 | |a Preuss, Ute |e investigator |4 oth | |
700 | 1 | |a Wedde, Marianne |e investigator |4 oth | |
700 | 1 | |a Mickienė, Auksė |e investigator |4 oth | |
700 | 1 | |a Gefenaitė, Giedrė |e investigator |4 oth | |
700 | 1 | |a Moren, Alain |e investigator |4 oth | |
700 | 1 | |a Nardone, Anthony |e investigator |4 oth | |
773 | 0 | 8 | |i Enthalten in |t Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin |d 1995 |g 28(2023), 47 vom: 23. Nov. |w (DE-627)NLM115683283 |x 1560-7917 |7 nnns |
773 | 1 | 8 | |g volume:28 |g year:2023 |g number:47 |g day:23 |g month:11 |
856 | 4 | 0 | |u http://dx.doi.org/10.2807/1560-7917.ES.2023.28.47.2300186 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 28 |j 2023 |e 47 |b 23 |c 11 |